Multitargeting Agents for Alzheimer's Disease
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 22228
Special Issue Editors
Interests: inhibitors of monoamine oxidases and cholinesterases; anti-amyloid agents; rational design, synthesis and biophysical characterization of multitargeting ligands against neurodegeneration; early-ADME profiling of multitarget-directed ligands (MTDLs) as neuroprotective agents; microwave-assisted organic synthesis of bioactive compounds; Alzheimer’s disease; Parkinson’s disease.
Interests: medicinal chemistry of multitarget-directed ligands (LTDLs) targeted at neurodegeneration; design, synthesis and structure-activity relationships of new oral anticoagulants (NOACs) and antiplatelet agents; biophysical characterization of kinetics and thermodynamics of interaction with different protein targets, involved in diseases onset and drug distribution profile
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
As life-expectancy gets higher, we are experiencing a dramatically increasing burden of age-related diseases for healthcare. Among these, Alzheimer’s disease (AD) represents a devastating, ultimately fatal neurodegenerative syndrome, the effective treatment of which remains elusive. The complex, multifaceted nature of AD prompted researchers to follow a paradigm shift towards multitargeting compounds, single molecular entities intentionally designed to correct two or more relevant AD deficits upon exerting different bioactivities with cooperative or additive effect.
This Special Issue aims to provide an overview of recent studies focused on innovative approaches to treat AD by means of multifunctional molecules able to modulate multiple disease-related targets as candidates for developing disease-modifying drugs.
Original papers, short communications as well as a limited number of review articles covering (but not limited to) the following topics are welcome: rational design, synthesis and screening campaign of multimodal enzymatic inhibitors; discovery of antioxidants or metal-chelating compounds as multifunctional neuro-protectants; development of hybrid multitargeting compounds; multipotent ligands from repositioning approaches; pharmacological evaluation of pleiotropic drugs from de novo design or repurposing approaches; computational strategies for designing multitargeting small molecules; nature-derived and nature-inspired multipotent hits.
Dr. Leonardo Pisani
Dr. Modesto De Candia
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer’s disease
- polypharmacology
- drug discovery
- rational design
- chemical synthesis
- natural products
- structure–activity relationships
- multi-target-directed molecules
- repositioning
- neuroprotectants
- chemoinformatics
- molecular modeling
- hybrid molecules
- biological activity
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.